Clinical Trial

Vitamin D Therapy to Prevent Recurrent Preeclampsia in High-Risk Pregnancies

Completed Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine whether vitamin D supplementation can reduce the recurrence of preeclampsia in pregnant women with a previous history of preeclampsia. The main questions the study aims to answer are: \- Does daily vitamin D supplementation reduce the recurrence of preeclampsia compared with a placebo? Researchers will randomly assign 146 eligible pregnant women to receive either vitamin D supplements or a placebo. The two groups will be compared to determine whether vitamin D lowers the risk of recurrent preeclampsia. Participants will: * Be randomly assigned to receive either 4000 IU oral vitamin D once daily or a matching placebo. * Take the assigned study medication daily until 36 weeks of gestation. * Attend follow-up visits every 2 weeks for blood pressure measurement and clinical assessment. * Have serum vitamin D levels measured every 4 weeks to monitor for vitamin D toxicity. * Undergo urine testing for protein if blood pressure is elevated to assess for preeclampsia. The results of this study will help determine whether vitamin D supplementation is an effective and safe strategy for preventing recurrent preeclampsia in women at high risk.
Trial Details
NCT Number NCT07717931
Lead Sponsor CMH Multan Institute of Medical Sciences
Conditions Preeclampsia
Enrollment 146 participants
Start Date 2025-08-01
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-21